{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:57:04Z","timestamp":1794916624695,"version":"4.9.1"},"reference-count":140,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alvimedica"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008877","name":"Biosensors","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Celonova"},{"DOI":"10.13039\/100007560","name":"Chiesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006479","name":"Cordis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"Medinol","id":[{"id":"https:\/\/ror.org\/03756wp26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Orbusneich","id":[{"id":"https:\/\/ror.org\/05g9af661","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Portola"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sinomed"},{"name":"Sahajanand Medical\n              Technologies"},{"DOI":"10.13039\/501100008645","name":"Terumo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention\u2013related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehz372","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T07:17:09Z","timestamp":1558423029000},"page":"2632-2653","source":"Crossref","is-referenced-by-count":589,"title":["Defining high bleeding risk in patients undergoing percutaneous coronary\n          intervention: a consensus document from the Academic Research Consortium for High Bleeding\n          Risk"],"prefix":"10.1093","volume":"40","author":[{"given":"Philip","family":"Urban","sequence":"first","affiliation":[{"name":"La Tour Hospital, Geneva, Switzerland"},{"name":"Cardiovascular European Research Center, Massy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Colleran","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Byrne","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Cardio-Thoracic-Vascular Department, Centro Alte Specialit\u00e0 e Trapianti, Catania, Italy"},{"name":"Azienda Ospedaliero Universitario \u201cVittorio Emanuele-Policlinico,\u201d University of Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuisset","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie, Centre Hospitalier Universitaire Timone and Inserm, Inra, Centre de recherche en cardiovasculaire et nutrition, Facult\u00e9 de M\u00e9decine, Aix-Marseille Universit\u00e9, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Cutlip","sequence":"additional","affiliation":[{"name":"Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Eerdmans","sequence":"additional","affiliation":[{"name":"Head of the Notified Body, DEKRA Certification B.V"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Farb","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA"},{"name":"Baim Institute for Clinical Research, Brookline, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gregson","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haude","sequence":"additional","affiliation":[{"name":"St\u00e4dtische Kliniken Neuss, Lukaskrankenhaus GmbH, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Seoul National University Hospital, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Konishi","sequence":"additional","affiliation":[{"name":"Office of Medical Devices 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Laschinger","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B","family":"Leon","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY"},{"name":"Cardiovascular Research Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P F Adrian","family":"Magee","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Mitsutake","sequence":"additional","affiliation":[{"name":"Office of Medical Devices 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Mylotte","sequence":"additional","affiliation":[{"name":"University Hospital and National University of Ireland, Galway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Pocock","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Price","sequence":"additional","affiliation":[{"name":"Scripps Clinic, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V","family":"Rao","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands"},{"name":"Cardialysis, Clinical Trial Management and Core Laboratories, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Varenne","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, H\u00f4pital Cochin, Assistance publique - h\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris-Cit\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Windhoevel","sequence":"additional","affiliation":[{"name":"Cardiovascular European Research Center, Massy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Yeh","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell W","family":"Krucoff","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC"},{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Morice","sequence":"additional","affiliation":[{"name":"Cardiovascular European Research Center, Massy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"2019091012094703500_ehz372-B1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","article-title":"2007 Focused update of the ACC\/AHA\/SCAI\n            2005 guideline update for percutaneous coronary intervention: a report of the American\n            College of Cardiology\/American Heart Association Task Force on Practice Guidelines: 2007\n            Writing Group to Review New Evidence and Update the ACC\/AHA\/SCAI 2005 Guideline Update\n            for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing\n            Committee","volume":"117","author":"King","year":"2008","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(08)61244-1","article-title":"Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting\n            stent with durable polymer for coronary revascularisation (LEADERS): a randomised\n            non-inferiority trial","volume":"372","author":"Windecker","year":"2008","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jcin.2011.08.010","article-title":"A new era of prospective real-world safety evaluation primary report of\n            XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval\n            post-market study)","volume":"4","author":"Krucoff","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in\n            patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in\n            high bleeding risk patients undergoing percutaneous coronary intervention? A\n            pre-specified analysis from the ZEUS trial","volume":"9","author":"Ariotti","year":"2016","journal-title":"JACC Cardiovasc\n            Interv"},{"key":"2019091012094703500_ehz372-B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary\n            artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.amjcard.2016.06.061","article-title":"Trends in bare-metal stent use in the United States in patients aged\n            >\/=65 years (from the CathPCI Registry)","volume":"118","author":"Rymer","year":"2016","journal-title":"Am J\n            Cardiol"},{"key":"2019091012094703500_ehz372-B8","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials:\n            a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B9","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a\n            consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcin.2011.03.008","article-title":"The Academic Research Consortium governance charter","volume":"4","author":"Krucoff","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B11","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/eurheartj\/ehv203","article-title":"Report of a European Society of Cardiology-European Association of\n            Percutaneous Cardiovascular Interventions task force on the evaluation of coronary\n            stents in Europe: executive summary","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"2019091012094703500_ehz372-B12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","article-title":"Randomized, double-blind, multicenter study of\n            the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of\n            native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II\n            trial","volume":"114","author":"Fajadet","year":"2006","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B13","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.03.005","article-title":"Clinical evaluation of the Resolute\n            zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native\n            coronary arteries: the RESOLUTE US clinical trial","volume":"57","author":"Yeung","year":"2011","journal-title":"J Am Coll\n            Cardiol"},{"key":"2019091012094703500_ehz372-B14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.299.16.1903","article-title":"Comparison of an everolimus-eluting stent and a\n            paclitaxel-eluting stent in patients with coronary artery disease: a randomized\n            trial","volume":"299","author":"Stone","year":"2008","journal-title":"JAMA"},{"key":"2019091012094703500_ehz372-B15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jacc.2011.02.016","article-title":"A prospective, randomized evaluation of a\n            novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized,\n            Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element]\n            for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial","volume":"57","author":"Stone","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B16","doi-asserted-by":"crossref","first-page":"e002372","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372","article-title":"Efficacy and safety of a novel bioabsorbable polymer-coated,\n            everolimus-eluting coronary stent: the EVOLVE II Randomized Trial","volume":"8","author":"Kereiakes","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.117.028885","article-title":"Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary\n            stents in patients with coronary artery disease: primary results from the BIONICS Trial\n            (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary\n            Stenosis)","volume":"136","author":"Kandzari","year":"2017","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting\n            stents versus thin, durable polymer everolimus-eluting stents in patients undergoing\n            coronary revascularisation (BIOFLOW V): a randomised trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B19","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/eurheartj\/ehp352","article-title":"Randomized, non-inferiority trial of three\n            limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting\n            and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4)\n            Trial","volume":"30","author":"Byrne","year":"2009","journal-title":"Eur Heart J"},{"key":"2019091012094703500_ehz372-B20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","article-title":"Comparison of zotarolimus-eluting and everolimus-eluting coronary\n            stents","volume":"363","author":"Serruys","year":"2010","journal-title":"N Engl J Med"},{"issue":"pt\n            A","key":"2019091012094703500_ehz372-B21","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.jacc.2014.04.013","article-title":"A randomized comparison of platinum\n            chromium-based everolimus-eluting stents versus cobalt chromium-based\n            zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention:\n            HOST-ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery\n            Stenosis-Safety & Effectiveness of Drug-Eluting Stents & antI-Platelet Regimen),\n            a randomized, controlled, noninferiority trial","volume":"63","author":"Park","year":"2014","journal-title":"J Am Coll\n            Cardiol"},{"key":"2019091012094703500_ehz372-B22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(10)60208-5","article-title":"Efficacy and safety of zotarolimus-eluting and\n            sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised\n            controlled superiority trial","volume":"375","author":"Rasmussen","year":"2010","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B23","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","article-title":"Very thin strut biodegradable polymer everolimus-eluting and\n            sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers\n            with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority\n            trial","volume":"388","author":"von Birgelen","year":"2016","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary\n            artery disease","volume":"375","author":"B\u00f8naa","year":"2016","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet\n            therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy\n            following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am\n            Coll Cardiol"},{"key":"2019091012094703500_ehz372-B26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of\n            drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss\n            After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B27","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for\n            coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of\n            dual-antiplatelet therapy after coronary stenting: a randomized multicenter\n            trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B29","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet\n            therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"2019091012094703500_ehz372-B30","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy\n            after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B31","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus\n            12-month dual antiplatelet therapy: the SECURITY randomized clinical\n            trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the\n            predicting bleeding complications in patients undergoing stent implantation and\n            subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of\n            individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed\n            by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12\n            months, followed by aspirin monotherapy for 12 months after implantation of a\n            drug-eluting stent: a multicentre, open-label, randomised superiority\n            trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-Month versus 12-month or longer dual\n            antiplatelet therapy after percutaneous coronary intervention in patients with acute\n            coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority\n            trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B35","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in\n            uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll\n            Cardiol"},{"key":"2019091012094703500_ehz372-B36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijcard.2017.10.103","article-title":"Development and external validation of a post-discharge bleeding risk score\n            in patients with acute coronary syndrome: the BleeMACS score","volume":"254","author":"Raposeiras-Roub\u00edn","year":"2018","journal-title":"Int J Cardiol"},{"key":"2019091012094703500_ehz372-B37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00535-013-0817-y","article-title":"Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose\n            aspirin users: development and validation of risk scores for either medication in two\n            large Dutch cohorts","volume":"49","author":"de Groot","year":"2014","journal-title":"J Gastroenterol"},{"key":"2019091012094703500_ehz372-B38","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents:\n            risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B39","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","article-title":"Risk score to predict serious bleeding in stable\n            outpatients with or at risk of atherothrombosis","volume":"31","author":"Ducrocq","year":"2010","journal-title":"Eur Heart\n            J"},{"key":"2019091012094703500_ehz372-B40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in\n            coronary artery disease developed in collaboration with EACTS: the Task Force for dual\n            antiplatelet therapy in coronary artery disease of the European Society of Cardiology\n            (ESC) and of the European Association for Cardio-Thoracic Surgery\n            (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2019091012094703500_ehz372-B41","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule\n            for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous\n            coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"2019091012094703500_ehz372-B42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable\n            cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B43","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacc.2007.06.022","article-title":"Coronary revascularization in the community: a population-based study, 1990\n            to 2004","volume":"50","author":"Gerber","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B44","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jacc.2016.12.005","article-title":"Trends in U.S. cardiovascular care: 2016 report from 4 ACC national\n            cardiovascular data\u00a0registries","volume":"69","author":"Masoudi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B45","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.amjcard.2006.06.026","article-title":"Comparison of outcomes of percutaneous\n            coronary interventions in patients of three age groups (<60, 60 to 80, and >80\n            years) (from the New York State Angioplasty Registry)","volume":"98","author":"Feldman","year":"2006","journal-title":"Am J\n            Cardiol"},{"key":"2019091012094703500_ehz372-B46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2017.04.079","article-title":"Drug-coated versus bare-metal stents for elderly patients: a predefined\n            sub-study of the LEADERS FREE trial","volume":"243","author":"Morice","year":"2017","journal-title":"Int J Cardiol"},{"key":"2019091012094703500_ehz372-B47","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial\n            infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients\n            Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding\n            Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B48","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary\n            syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B49","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjcard.2010.12.009","article-title":"In-hospital major bleeding during ST-elevation and non-ST-elevation\n            myocardial infarction care: derivation and validation of a model from the ACTION\n            Registry(R)-GWTG","volume":"107","author":"Mathews","year":"2011","journal-title":"Am J Cardiol"},{"key":"2019091012094703500_ehz372-B50","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcin.2013.04.016","article-title":"An updated bleeding model to predict the risk of post-procedure bleeding\n            among patients undergoing percutaneous coronary intervention: a report using an expanded\n            bleeding definition from the National Cardiovascular Data Registry CathPCI\n            Registry","volume":"6","author":"Rao","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B51","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/eurheartj\/ehw683","article-title":"Personalising the decision for prolonged dual antiplatelet therapy:\n            development, validation and potential impact of prognostic models for cardiovascular\n            events and bleeding in myocardial infarction survivors","volume":"38","author":"Pasea","year":"2017","journal-title":"Eur\n            Heart J"},{"key":"2019091012094703500_ehz372-B52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2017.10.015","article-title":"Short-term versus long-term dual antiplatelet therapy after drug-eluting\n            stent implantation in elderly patients: a meta-analysis of individual participant data\n            from\u00a06\u00a0randomized trials","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with\n            atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary\n            interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with\n            oral anticoagulation undergoing percutaneous coronary intervention","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients\n            taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an\n            open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B56","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after\n            drug-eluting stent implantation: the ISAR-TRIPLE Trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am\n            Coll Cardiol"},{"key":"2019091012094703500_ehz372-B57","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing\n            PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B58","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic\n            therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl\n            J Med"},{"key":"2019091012094703500_ehz372-B59","doi-asserted-by":"crossref","first-page":"e001380","DOI":"10.1161\/JAHA.114.001380","article-title":"Validated contemporary risk model of acute kidney injury in patients\n            undergoing percutaneous coronary interventions: insights from the National\n            Cardiovascular Data Registry Cath-PCI Registry","volume":"3","author":"Tsai","year":"2014","journal-title":"J Am Heart\n            Assoc"},{"key":"2019091012094703500_ehz372-B60","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jcin.2009.05.018","article-title":"Impact of chronic kidney disease on early (30-day) and late (1-year)\n            outcomes of patients with acute coronary syndromes treated with alternative\n            antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent\n            Intervention Triage strategY) substudy","volume":"2","author":"Mehran","year":"2009","journal-title":"JACC Cardiovasc\n            Interv"},{"key":"2019091012094703500_ehz372-B61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jcin.2011.06.012","article-title":"Long-term impact of chronic kidney disease in patients with ST-segment\n            elevation myocardial infarction treated with primary percutaneous coronary intervention:\n            the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute\n            Myocardial Infarction) trial","volume":"4","author":"Saltzman","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcin.2008.06.012","article-title":"In-hospital and 1-year outcomes among percutaneous\n            coronary intervention patients with chronic kidney disease in the era of drug-eluting\n            stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events)\n            registry","volume":"2","author":"Latif","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B63","doi-asserted-by":"crossref","first-page":"e006144","DOI":"10.1161\/CIRCINTERVENTIONS.117.006144","article-title":"Incidence, patterns, and impact of dual antiplatelet therapy cessation\n            among patients with and without chronic kidney disease undergoing percutaneous coronary\n            intervention: results from the PARIS Registry (Patterns of Non-Adherence to\n            Anti-Platelet Regimens in Stented Patients)","volume":"11","author":"Baber","year":"2018","journal-title":"Circ Cardiovasc\n            Interv"},{"key":"2019091012094703500_ehz372-B64","doi-asserted-by":"crossref","first-page":"e001683","DOI":"10.1161\/CIRCINTERVENTIONS.115.001683","article-title":"Prevalence and impact of high platelet reactivity in chronic kidney\n            disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting\n            Stents registry","volume":"8","author":"Baber","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B65","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1161\/CIRCINTERVENTIONS.111.965749","article-title":"The impact of anemia on long-term clinical outcome in patients undergoing\n            revascularization with the unrestricted use of drug-eluting stents","volume":"5","author":"Pilgrim","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.thromres.2018.05.024","article-title":"Anemia in patients with acute coronary syndromes treated with prasugrel or\n            ticagrelor: insights from the RENAMI registry","volume":"167","author":"Guerrero","year":"2018","journal-title":"Thromb\n            Res"},{"key":"2019091012094703500_ehz372-B67","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.amjcard.2016.05.059","article-title":"Meta-analysis of the prognostic impact of anemia in patients undergoing\n            percutaneous coronary intervention","volume":"118","author":"Kwok","year":"2016","journal-title":"Am J Cardiol"},{"key":"2019091012094703500_ehz372-B68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer\n            bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a\n            randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"2019091012094703500_ehz372-B70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal\n            bleeding","volume":"368","author":"Villanueva","year":"2013","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B71","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients\n            with thrombocytopenia: a clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur Heart\n            J"},{"key":"2019091012094703500_ehz372-B72","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.jcin.2018.05.033","article-title":"Impact of chronic thrombocytopenia on\u00a0in-hospital outcomes after\n            percutaneous coronary\u00a0intervention","volume":"11","author":"Ayoub","year":"2018","journal-title":"JACC Cardiovasc\n            Interv"},{"key":"2019091012094703500_ehz372-B73","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.amjcard.2018.02.010","article-title":"Impact of baseline thrombocytopenia on bleeding and mortality after\n            percutaneous coronary intervention","volume":"121","author":"Ito","year":"2018","journal-title":"Am J Cardiol"},{"key":"2019091012094703500_ehz372-B74","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ahj.2010.11.001","article-title":"Impact of baseline thrombocytopenia on the early and late outcomes after\n            ST-elevation myocardial infarction treated with primary angioplasty: analysis from the\n            Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction\n            (HORIZONS-AMI) trial","volume":"161","author":"Hakim","year":"2011","journal-title":"Am Heart J"},{"key":"2019091012094703500_ehz372-B75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ejh.12498","article-title":"Prevention and treatment of atherosclerosis in haemophilia: how to balance\n            risk of bleeding with risk of ischaemic events","volume":"94","author":"de Raucourt","year":"2015","journal-title":"Eur J\n            Haematol"},{"key":"2019091012094703500_ehz372-B76","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2017-05-782029","article-title":"Advances in the diagnosis and treatment of von Willebrand\n            disease","volume":"130","author":"Sharma","year":"2017","journal-title":"Blood"},{"key":"2019091012094703500_ehz372-B77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0032-1301416","article-title":"Atherothrombosis in von Willebrand disease: an analysis of the literature\n            and implications for clinical management","volume":"38","author":"Franchini","year":"2012","journal-title":"Semin Thromb\n            Hemost"},{"key":"2019091012094703500_ehz372-B78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ccd.27255","article-title":"Coronary angiography with or without percutaneous coronary intervention in\n            patients with hemophilia: systematic review","volume":"92","author":"Boehnel","year":"2018","journal-title":"Catheter Cardiovasc\n            Interv"},{"key":"2019091012094703500_ehz372-B79","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in\n            adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"key":"2019091012094703500_ehz372-B80","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.amjcard.2016.03.010","article-title":"Percutaneous coronary intervention in patients with end-stage liver\n            disease","volume":"117","author":"Singh","year":"2016","journal-title":"Am J Cardiol"},{"key":"2019091012094703500_ehz372-B81","first-page":"39","article-title":"The pathophysiology of thrombocytopenia in chronic liver\n            disease","volume":"8","author":"Mitchell","year":"2016","journal-title":"Hepat Med"},{"key":"2019091012094703500_ehz372-B82","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182371258","article-title":"Coronary artery stents and antiplatelet therapy in patients with\n            cirrhosis","volume":"46","author":"Russo","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"2019091012094703500_ehz372-B83","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/lt.23873","article-title":"Role of cardiac catheterization and percutaneous coronary intervention in\n            the preoperative assessment and management of patients before orthotopic liver\n            transplantation","volume":"20","author":"Maddur","year":"2014","journal-title":"Liver Transpl"},{"key":"2019091012094703500_ehz372-B84","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.amjcard.2016.07.025","article-title":"Temporal trends, predictors, and outcomes of in-hospital gastrointestinal\n            bleeding associated with percutaneous coronary intervention","volume":"118","author":"Patel","year":"2016","journal-title":"Am\n            J Cardiol"},{"key":"2019091012094703500_ehz372-B85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.14121","article-title":"Patients with cirrhosis who have coronary artery disease treated with\n            cardiac stents have high rates of gastrointestinal bleeding, but no increased\n            mortality","volume":"46","author":"Krill","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2019091012094703500_ehz372-B86","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of\n            major bleeding in clinical investigations of antihemostatic medicinal products in\n            non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2019091012094703500_ehz372-B87","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically\n            relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and\n            venous thromboembolic disease in non-surgical patients: communication from the SSC of\n            the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2019091012094703500_ehz372-B88","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.29318","article-title":"Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic\n            hepatitis B patients on antiviral treatment","volume":"66","author":"Lee","year":"2017","journal-title":"Hepatology"},{"key":"2019091012094703500_ehz372-B89","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver\n            disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"2019091012094703500_ehz372-B90","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin\n            Surg"},{"key":"2019091012094703500_ehz372-B91","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal\n            varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"2019091012094703500_ehz372-B92","article-title":"Percutaneous coronary intervention in cancer patients: a report of the\n            prevalence and outcomes in the United States","author":"Potts","journal-title":"Eur Heart J"},{"key":"2019091012094703500_ehz372-B93","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/CIRCINTERVENTIONS.109.928721","article-title":"Incidence, predictors, and prognostic implications of hospitalization for\n            late bleeding after percutaneous coronary intervention for patients older than 65\n            years","volume":"3","author":"Ko","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B94","first-page":"412","article-title":"Ascertainment, classification, and impact of\n            neoplasm detection during prolonged treatment with dual antiplatelet therapy with\n            prasugrel vs. clopidogrel following acute coronary syndrome","volume":"37","author":"Roe","year":"2016","journal-title":"Eur\n            Heart J"},{"key":"2019091012094703500_ehz372-B95","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jacc.2013.01.007","article-title":"Population trends in percutaneous coronary intervention: 20-year results\n            from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)","volume":"61","author":"Fokkema","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B96","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcin.2017.05.042","article-title":"In-hospital outcomes of percutaneous\u00a0coronary intervention in\u00a0America\u2019s\n            safety\u00a0net: insights from the NCDR Cath-PCI Registry","volume":"10","author":"Acharya","year":"2017","journal-title":"JACC\n            Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B97","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose\n            clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous\n            coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised\n            factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B98","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute\n            coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B99","year":"2009"},{"key":"2019091012094703500_ehz372-B100","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","article-title":"Ticagrelor versus clopidogrel in patients with acute\n            coronary syndromes and a history of stroke or transient ischemic attack","volume":"125","author":"James","year":"2012","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B101","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with\n            prior ischemic stroke","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"2019091012094703500_ehz372-B102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or\n            transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in\n            acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J\n          Med"},{"key":"2019091012094703500_ehz372-B104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke\n            and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel\n            alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients\n            (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B106","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus\n            clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B107","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar\n            stroke","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B108","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the early\n            management of patients with acute ischemic stroke: a guideline for healthcare\n            professionals from the American Heart Association\/American Stroke\n            Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"2019091012094703500_ehz372-B109","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and\n            transient ischemic attack: a guideline for healthcare professionals from the American\n            Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"2019091012094703500_ehz372-B110","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1161\/STR.0000000000000134","article-title":"Management of brain\n            arteriovenous malformations: a scientific statement for healthcare professionals from\n            the American Heart Association\/American Stroke Association","volume":"48","author":"Derdeyn","year":"2017","journal-title":"Stroke"},{"key":"2019091012094703500_ehz372-B111","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1212\/WNL.0000000000000688","article-title":"Untreated brain arteriovenous malformation:\n            patient-level meta-analysis of hemorrhage predictors","volume":"83","author":"Kim","year":"2014","journal-title":"Neurology"},{"key":"2019091012094703500_ehz372-B112","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)62302-8","article-title":"Medical management with or without\n            interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a\n            multicentre, non-blinded, randomised trial","volume":"383","author":"Mohr","year":"2014","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B113","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1161\/CIRCULATIONAHA.113.003675","article-title":"Management of antiplatelet therapy in patients with coronary artery disease\n            requiring cardiac and noncardiac surgery","volume":"128","author":"Capodanno","year":"2013","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B114","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.jacc.2017.02.012","article-title":"Use of antiplatelet therapy\/DAPT for\u00a0post-PCI patients undergoing\n            noncardiac surgery","volume":"69","author":"Banerjee","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B115","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMoa1401105","article-title":"Aspirin in patients undergoing noncardiac\n            surgery","volume":"370","author":"Devereaux","year":"2014","journal-title":"N Engl J Med"},{"key":"2019091012094703500_ehz372-B116","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","article-title":"2014 ESC\/ESA guidelines on non-cardiac surgery:\n            cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery:\n            cardiovascular assessment and management of the European Society of Cardiology (ESC) and\n            the European Society of Anaesthesiology (ESA)","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart\n            J"},{"key":"2019091012094703500_ehz372-B117","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused\u00a0update on duration of dual\u00a0antiplatelet\n            therapy in patients with coronary artery disease: a report of the American College of\n            Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice\n            Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2019091012094703500_ehz372-B118","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2017.10.051","article-title":"A\n            multidisciplinary approach on the\u00a0perioperative antithrombotic management\u00a0of patients\n            with coronary\u00a0stents undergoing surgery: surgery after stenting 2","volume":"11","author":"Rossini","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B119","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.acvd.2017.12.004","article-title":"Management of\n            antiplatelet therapy in patients undergoing elective invasive procedures: proposals from\n            the French Working Group on Perioperative Hemostasis (GIHP) and the French Study Group\n            on Thrombosis and Hemostasis (GFHT): in collaboration with the French Society for\n            Anesthesia and Intensive Care (SFAR)","volume":"111","author":"Godier","year":"2018","journal-title":"Arch Cardiovasc\n            Dis"},{"key":"2019091012094703500_ehz372-B120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.recesp.2018.01.001","article-title":"Perioperative and periprocedural management of antithrombotic therapy:\n            consensus document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH,\n            SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT\n            and AEU","volume":"71","author":"Vivas","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2019091012094703500_ehz372-B121","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and\n            paclitaxel-eluting stents in routine clinical practice: data from a large\n            two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B122","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/CIRCULATIONAHA.108.808311","article-title":"Antiplatelet therapy and stent thrombosis\n            after sirolimus-eluting stent implantation","volume":"119","author":"Kimura","year":"2009","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B123","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.avsg.2016.07.099","article-title":"Regional variation in postoperative myocardial\n            infarction in patients undergoing vascular surgery in the United States","volume":"40","author":"Steely","year":"2017","journal-title":"Ann Vasc Surg"},{"key":"2019091012094703500_ehz372-B124","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1074248417751070","article-title":"Cardiorenal safety of OTC analgesics","volume":"23","author":"White","year":"2018","journal-title":"J Cardiovasc\n            Pharmacol Ther"},{"key":"2019091012094703500_ehz372-B125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00045391-200007020-00008","article-title":"Gastrointestinal complications of prescription and over-the-counter\n            nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database: Arthritis,\n            Rheumatism, and Aging Medical Information System","volume":"7","author":"Singh","year":"2000","journal-title":"Am J\n            Ther"},{"key":"2019091012094703500_ehz372-B126","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1053\/j.gastro.2017.10.049","article-title":"Mechanisms of damage to the gastrointestinal tract from\u00a0nonsteroidal\n            anti-inflammatory drugs","volume":"154","author":"Bjarnason","year":"2018","journal-title":"Gastroenterology"},{"key":"2019091012094703500_ehz372-B127","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ajg.2009.115","article-title":"Guidelines for prevention of NSAID-related ulcer\n            complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2019091012094703500_ehz372-B128","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2014.06.007","article-title":"Risk of upper gastrointestinal bleeding from different drug\n            combinations","volume":"147","author":"Masclee","year":"2014","journal-title":"Gastroenterology"},{"key":"2019091012094703500_ehz372-B129","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/S0140-6736(17)30981-9","article-title":"Gastrointestinal safety of celecoxib versus naproxen in patients with\n            cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN):\n            an industry-independent, double-blind, double-dummy, randomised trial","volume":"389","author":"Chan","year":"2017","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B130","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory\n            drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized\n            controlled trial: Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"2019091012094703500_ehz372-B131","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/aje\/kwx061","article-title":"Agreement between 35 published frailty scores in the general\n            population","volume":"186","author":"Aguayo","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2019091012094703500_ehz372-B132","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.jcin.2018.08.028","article-title":"The association of frailty with in-hospital bleeding among older\n            adults\u00a0with acute myocardial infarction: insights from the ACTION\n            Registry","volume":"11","author":"Dodson","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B133","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jjcc.2016.05.003","article-title":"Incidence and predictors of bleeding complications after percutaneous\n            coronary intervention","volume":"69","author":"Numasawa","year":"2017","journal-title":"J Cardiol"},{"key":"2019091012094703500_ehz372-B134","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in\n            Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"Saito","year":"2014","journal-title":"Circ J"},{"key":"2019091012094703500_ehz372-B135","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ahj.2015.09.017","article-title":"An international comparison of patients undergoing\n            percutaneous coronary intervention: a collaborative study of the National Cardiovascular\n            Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular\n            Studies (JCD-KiCS)","volume":"170","author":"Kohsaka","year":"2015","journal-title":"Am Heart J"},{"key":"2019091012094703500_ehz372-B136","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1676545","article-title":"Racial differences in ischaemia\/bleeding risk trade-off during\n            anti-platelet therapy: individual patient level landmark meta-analysis from seven\n            RCTs","volume":"119","author":"Kang","year":"2019","journal-title":"Thromb Haemost"},{"key":"2019091012094703500_ehz372-B137","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","article-title":"Incidence, prognostic impact, and influence of antithrombotic therapy on\n            access and nonaccess site bleeding in percutaneous coronary\n          intervention","volume":"4","author":"Verheugt","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2019091012094703500_ehz372-B138","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with\n            ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous\n            coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup\n            analysis","volume":"122","author":"Steg","year":"2010","journal-title":"Circulation"},{"key":"2019091012094703500_ehz372-B139","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in\n            patients undergoing percutaneous coronary intervention for ST-elevation myocardial\n            infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"2019091012094703500_ehz372-B140","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after\n            percutaneous coronary intervention (PARIS): 2 year results from a prospective\n            observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehz372\/28771459\/ehz372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/31\/2632\/29514953\/ehz372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T09:39:09Z","timestamp":1569145149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/31\/2632\/5492739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":140,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2019,5,22]]},"published-print":{"date-parts":[[2019,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz372","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,14]]},"published":{"date-parts":[[2019,5,22]]}}}